Literature DB >> 15632169

Constitutive activation of GSK3 down-regulates glycogen synthase abundance and glycogen deposition in rat skeletal muscle cells.

Katrina MacAulay1, Anne S Blair, Eric Hajduch, Tatsuo Terashima, Otto Baba, Calum Sutherland, Harinder S Hundal.   

Abstract

The effects of inhibition or constitutive activation of glycogen synthase kinase-3 (GSK3) on glycogen synthase (GS) activity, abundance, and glycogen deposition in L6 rat skeletal muscle cells were investigated. GS protein expression increased approximately 5-fold during differentiation of L6 cells (comparing cells at the end of day 5 with those at the beginning of day 3). However, exposure of undifferentiated myoblasts (day 3) to 50 microM SB-415286, a GSK3 inhibitor, led to a significant elevation in GS protein that was not accompanied by changes in the abundance of GLUT4, another late differentiation marker. In contrast, stable expression of a constitutively active form of GSK3beta (GSK3S9A) led to a significant reduction (approximately 80%) in GS protein that was antagonized by SB-415286. Inhibition of GSK3 or expression of the constitutively active GSK3S9A did not result in any detectable changes in GS mRNA abundance. However, the increase in GS protein in undifferentiated myoblasts or that seen following incubation of cells expressing GSK3S9A with GSK3 inhibitors was blocked by cycloheximide suggesting that GSK3 influences GS abundance possibly via control of mRNA translation. Consistent with the reduction in GS protein, cells expressing GSK3S9A were severely glycogen depleted as judged using a specific glycogen-staining antibody. Inhibiting GSK3 in wild-type or GSK3S9A-expressing cells using SB-415286 resulted in an attendant activation of GS, but not that of glucose transport. However, GS activation alone was insufficient for stimulating glycogen deposition. Only when muscle cells were incubated simultaneously with insulin and SB-415286 or with lithium (which stimulates GS and glucose transport) was an increase in glycogen accretion observed. Our findings suggest that GSK3 activity is an important determinant of GS protein expression and that while glycogen deposition in muscle cells is inherently dependent upon the activity/expression of GS, glucose transport is a key rate-determining step in this process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15632169     DOI: 10.1074/jbc.M411648200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Beta(2)-Adrenergic activation increases glycogen synthesis in L6 skeletal muscle cells through a signalling pathway independent of cyclic AMP.

Authors:  D L Yamamoto; D S Hutchinson; T Bengtsson
Journal:  Diabetologia       Date:  2006-11-22       Impact factor: 10.122

2.  AMPK Facilitates Nuclear Accumulation of Nrf2 by Phosphorylating at Serine 550.

Authors:  Min Sung Joo; Won Dong Kim; Ki Young Lee; Ji Hyun Kim; Ja Hyun Koo; Sang Geon Kim
Journal:  Mol Cell Biol       Date:  2016-06-29       Impact factor: 4.272

3.  Molecular and functional characterization of glycogen synthase in the porcine satellite cells under insulin treatment.

Authors:  Linjie Wang; Yuanzhu Xiong; Bo Zuo; Minggang Lei; Zhuqing Ren; Dequan Xu
Journal:  Mol Cell Biochem       Date:  2011-09-20       Impact factor: 3.396

Review 4.  The PI3K pathway in B cell metabolism.

Authors:  Julia Jellusova; Robert C Rickert
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-08-05       Impact factor: 8.250

5.  Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis.

Authors:  Edward J McManus; Kei Sakamoto; Laura J Armit; Leah Ronaldson; Natalia Shpiro; Rodolfo Marquez; Dario R Alessi
Journal:  EMBO J       Date:  2005-03-24       Impact factor: 11.598

6.  Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease.

Authors:  Nina Raben; Cynthia Schreiner; Rebecca Baum; Shoichi Takikita; Sengen Xu; Tao Xie; Rachel Myerowitz; Masaaki Komatsu; Jack H Van der Meulen; Kanneboyina Nagaraju; Evelyn Ralston; Paul H Plotz
Journal:  Autophagy       Date:  2010-11       Impact factor: 16.016

7.  iNOS inhibitor, L-NIL, reverses burn-induced glycogen synthase kinase-3β activation in skeletal muscle of rats.

Authors:  Masao Kaneki; Yuji Fukushima; Shohei Shinozaki; Makiko Fukaya; Mayu Habiro; Nobuyuki Shimizu; Kyungho Chang; Shingo Yasuhara; J A Jeevendra Martyn
Journal:  Metabolism       Date:  2012-09-17       Impact factor: 8.694

8.  SIRT2 deacetylase regulates the activity of GSK3 isoforms independent of inhibitory phosphorylation.

Authors:  Mohsen Sarikhani; Sneha Mishra; Sangeeta Maity; Chaithanya Kotyada; Donald Wolfgeher; Mahesh P Gupta; Mahavir Singh; Nagalingam R Sundaresan
Journal:  Elife       Date:  2018-03-05       Impact factor: 8.140

9.  Dynamic telomerase gene suppression via network effects of GSK3 inhibition.

Authors:  Alan E Bilsland; Stacey Hoare; Katrina Stevenson; Jane Plumb; Natividad Gomez-Roman; Claire Cairney; Sharon Burns; Kyle Lafferty-Whyte; Jon Roffey; Tim Hammonds; W Nicol Keith
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

10.  Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation.

Authors:  Svetlana Kotliarova; Sandra Pastorino; Lara C Kovell; Yuri Kotliarov; Hua Song; Wei Zhang; Rolanda Bailey; Dragan Maric; Jean Claude Zenklusen; Jeongwu Lee; Howard A Fine
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.